Skip to main content
Top
Published in: Endocrine 3/2018

01-12-2018 | Original Article

Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s

Authors: Dania Hirsch, Ilan Shimon, Yossi Manisterski, Nirit Aviran-Barak, Oren Amitai, Varda Nadler, Sandra Alboim, Vered Kopel, Gloria Tsvetov

Published in: Endocrine | Issue 3/2018

Login to get access

Abstract

Purpose

The most common etiology of Cushing’s syndrome (CS) is an ACTH-producing pituitary adenoma (pitCS), reported as 2–3 times more frequent than primary adrenal CS (adrCS). We aimed to analyze and compare features of patients with pitCS and adrCS.

Methods

A retrospective file review of 196 consecutive patients (age 46.8 ± 15.6 years, 76% female) diagnosed with CS in 2000–2017 and followed for 5.2 ± 4.2 years; 109 (55.6%) had pitCS and 76 (38.8%) adrCS. Epidemiologic, clinical and biochemical factors were compared between and within the pitCS and adrCS groups.

Results

The relative proportion of pitCS to adrCS (1.4) was lower than previously reported and gradually decreased during the study years to only 1.2 in 2012–2017. The most common reason for CS screening was weight-gain in the pitCS group (48.6%) and adrenal incidentaloma in the adrCS group (39.5%). The pitCS patients were diagnosed at younger age (42.5 ± 15.1 vs. 51.6 ± 15.1 years, p < 0.001) and had lower prevalence of hypertension (51.4 vs. 74%, p = 0.005). There was no between-group difference in severity of hypercortisoluria. Within the adrCS group, patients diagnosed after detection of an adrenal incidentaloma had milder hypercortisoluria than the remaining patients, presented with smaller adrenal lesions (35.9 ± 16.3 vs. 49.1 ± 33.7 cm, p = 0.04), and received post-adrenalectomy glucocorticoid treatment for shorter periods (13 ± 11.6 vs. 31 ± 40 months, p = 0.04).

Conclusions

The relative proportion of adrCS to pitCS is rising, probably because of an increasing detection of cortisol-secreting adrenal incidentalomas associated with milder hypercortisolism. There is no difference between pitCS and adrCS in the severity of hypercortisoluria, although significant clinical differences were found.
Literature
1.
go back to reference J. Lindholm, S. Juul, J.O. Jørgensen, J. Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jørgensen, M. Kosteljanetz, L. Kristensen, P. Laurberg, K. Schmidt, J. Weeke, Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86, 117–123 (2001)PubMed J. Lindholm, S. Juul, J.O. Jørgensen, J. Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jørgensen, M. Kosteljanetz, L. Kristensen, P. Laurberg, K. Schmidt, J. Weeke, Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86, 117–123 (2001)PubMed
2.
go back to reference C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jørgensen, Epidemiology of Cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 1–5 (2010)CrossRef C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jørgensen, Epidemiology of Cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 1–5 (2010)CrossRef
3.
go back to reference D. Hirsch, G. Tsvetov, Y. Manisterski, N. Aviran-Barak, V. Nadler, S. Alboim, V. Kopel, Incidence of Cushing’s syndrome in patients with significant hypercortisoluria. Eur. J. Endocrinol. 176, 41–48 (2017)CrossRef D. Hirsch, G. Tsvetov, Y. Manisterski, N. Aviran-Barak, V. Nadler, S. Alboim, V. Kopel, Incidence of Cushing’s syndrome in patients with significant hypercortisoluria. Eur. J. Endocrinol. 176, 41–48 (2017)CrossRef
4.
go back to reference A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRef A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRef
5.
go back to reference E. Valassi, A. Santos, M. Yaneva, M. Tóth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, ERCUSYN Study Group. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165, 383–392 (2011)CrossRef E. Valassi, A. Santos, M. Yaneva, M. Tóth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, ERCUSYN Study Group. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165, 383–392 (2011)CrossRef
6.
go back to reference E. Valassi, H. Franz, T. Brue, R.A. Feelders, R. Netea-Maier, S. Tsagarakis, S.M. Webb, M. Yaneva, M. Reincke, M. Droste, I. Komerdus, D. Maiter, D. Kastelan, P. Chanson, M. Pfeifer, C.J. Strasburger, M. Tóth, O. Chabre, A. Tabarin, M. Krsek, C. Fajardo, M. Bolanowski, A. Santos, J.A. Wass, P.J. Trainer, ERCUSYN Study Group. Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur. J. Endocrinol. 176, 613–624 (2017)CrossRef E. Valassi, H. Franz, T. Brue, R.A. Feelders, R. Netea-Maier, S. Tsagarakis, S.M. Webb, M. Yaneva, M. Reincke, M. Droste, I. Komerdus, D. Maiter, D. Kastelan, P. Chanson, M. Pfeifer, C.J. Strasburger, M. Tóth, O. Chabre, A. Tabarin, M. Krsek, C. Fajardo, M. Bolanowski, A. Santos, J.A. Wass, P.J. Trainer, ERCUSYN Study Group. Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur. J. Endocrinol. 176, 613–624 (2017)CrossRef
7.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRef L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRef
8.
go back to reference G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRef G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRef
9.
go back to reference H. Falhammar, J. Calissendorff, C. Höybye, Frequency of Cushing’s syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center. Endocrine 55, 296–302 (2017)CrossRef H. Falhammar, J. Calissendorff, C. Höybye, Frequency of Cushing’s syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center. Endocrine 55, 296–302 (2017)CrossRef
10.
11.
go back to reference C. Invitti, F. Pecori Giraldi, M. De Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J. Clin. Endocrinol. Metab. 84, 440–448 (1999)PubMed C. Invitti, F. Pecori Giraldi, M. De Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J. Clin. Endocrinol. Metab. 84, 440–448 (1999)PubMed
12.
go back to reference M.M. Grumbach, B.M. Biller, G.D. Braunstein, K.K. Campbell, J.A. Carney, P.A. Godley, E.L. Harris, J.K. Lee, Y.C. Oertel, M.C. Posner, J.A. Schlechte, H.S. Wieand, Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med. 138, 424–429 (2003)CrossRef M.M. Grumbach, B.M. Biller, G.D. Braunstein, K.K. Campbell, J.A. Carney, P.A. Godley, E.L. Harris, J.K. Lee, Y.C. Oertel, M.C. Posner, J.A. Schlechte, H.S. Wieand, Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med. 138, 424–429 (2003)CrossRef
13.
go back to reference M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A. Sahdev, A. Tabarin, M. Terzolo, S. Tsagarakis, O.M. Dekkers, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175, G1–G34 (2016)CrossRef M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A. Sahdev, A. Tabarin, M. Terzolo, S. Tsagarakis, O.M. Dekkers, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175, G1–G34 (2016)CrossRef
14.
go back to reference C.M. Berr, G. Di Dalmazi, A. Osswald, K. Ritzel, M. Bidlingmaier, L.L. Geyer, M. Treitl, K. Hallfeldt, W. Rachinger, N. Reisch, R. Blaser, J. Schopohl, F. Beuschlein, M. Reincke, Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology. J. Clin. Endocrinol. Metab. 100, 1300–1308 (2015)CrossRef C.M. Berr, G. Di Dalmazi, A. Osswald, K. Ritzel, M. Bidlingmaier, L.L. Geyer, M. Treitl, K. Hallfeldt, W. Rachinger, N. Reisch, R. Blaser, J. Schopohl, F. Beuschlein, M. Reincke, Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology. J. Clin. Endocrinol. Metab. 100, 1300–1308 (2015)CrossRef
15.
go back to reference G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, S.R. Bornstein, The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25, 309–340 (2004)CrossRef G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, S.R. Bornstein, The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25, 309–340 (2004)CrossRef
16.
go back to reference F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini, A. Ali, M. Giovagnetti, G. Opocher, A. Angeli, A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab. 85, 637–644 (2000)PubMed F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini, A. Ali, M. Giovagnetti, G. Opocher, A. Angeli, A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab. 85, 637–644 (2000)PubMed
17.
go back to reference S. Bovio, A. Cataldi, G. Reimondo, P. Sperone, S. Novello, A. Berruti, P. Borasio, C. Fava, L. Dogliotti, G.V. Scagliotti, A. Angeli, M. Terzolo, Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 29, 298–302 (2006)CrossRef S. Bovio, A. Cataldi, G. Reimondo, P. Sperone, S. Novello, A. Berruti, P. Borasio, C. Fava, L. Dogliotti, G.V. Scagliotti, A. Angeli, M. Terzolo, Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 29, 298–302 (2006)CrossRef
18.
go back to reference N. Benitah, B.M. Yeh, A. Qayyum, G. Williams, R.S. Breiman, F.V. Coakley, Minor morphologic abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer. Radiology 235, 517–522 (2005)CrossRef N. Benitah, B.M. Yeh, A. Qayyum, G. Williams, R.S. Breiman, F.V. Coakley, Minor morphologic abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer. Radiology 235, 517–522 (2005)CrossRef
19.
go back to reference G. Di Dalmazi, C.M. Berr, M. Fassnacht, F. Beuschlein, M. Reincke, Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J. Clin. Endocrinol. Metab. 99, 2637–2645 (2014)CrossRef G. Di Dalmazi, C.M. Berr, M. Fassnacht, F. Beuschlein, M. Reincke, Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J. Clin. Endocrinol. Metab. 99, 2637–2645 (2014)CrossRef
20.
go back to reference F. Ceccato, G. Antonelli, A.C. Frigo, D. Regazzo, M. Plebani, M. Boscaro, C. Scaroni, First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J. Endocrinol. Invest. 40, 753–760 (2017)CrossRef F. Ceccato, G. Antonelli, A.C. Frigo, D. Regazzo, M. Plebani, M. Boscaro, C. Scaroni, First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J. Endocrinol. Invest. 40, 753–760 (2017)CrossRef
21.
go back to reference J.W. Findling, H. Raff, D.C. Aron, The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J. Clin. Endocrinol. Metab. 89(3), 1222–1226 (2004). MarCrossRef J.W. Findling, H. Raff, D.C. Aron, The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J. Clin. Endocrinol. Metab. 89(3), 1222–1226 (2004). MarCrossRef
22.
go back to reference R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36, 385–486 (2015)CrossRef R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36, 385–486 (2015)CrossRef
23.
go back to reference S.G. Creemers, L.J. Hofland, S.W. Lamberts, R.A. Feelders, Cushing’s syndrome: an update on current pharmacotherapy and future directions. Expert Opin. Pharmacother. 16, 1829–1844 (2015)CrossRef S.G. Creemers, L.J. Hofland, S.W. Lamberts, R.A. Feelders, Cushing’s syndrome: an update on current pharmacotherapy and future directions. Expert Opin. Pharmacother. 16, 1829–1844 (2015)CrossRef
24.
go back to reference N.M. Albiger, F. Ceccato, M. Zilio, M. Barbot, G. Occhi, S. Rizzati, A. Fassina, F. Mantero, M. Boscaro, M. Iacobone, C. Scaroni, An analysis of different therapeutic options in patients with Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin. Endocrinol. (Oxf.). 82, 808–815 (2015)CrossRef N.M. Albiger, F. Ceccato, M. Zilio, M. Barbot, G. Occhi, S. Rizzati, A. Fassina, F. Mantero, M. Boscaro, M. Iacobone, C. Scaroni, An analysis of different therapeutic options in patients with Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin. Endocrinol. (Oxf.). 82, 808–815 (2015)CrossRef
25.
go back to reference E. Van Cauter, S. Refetoff, Evidence for two subtypes of Cushing’s disease based on the analysis of episodic cortisol secretion. N. Engl. J. Med. 312, 1343–1349 (1985)CrossRef E. Van Cauter, S. Refetoff, Evidence for two subtypes of Cushing’s disease based on the analysis of episodic cortisol secretion. N. Engl. J. Med. 312, 1343–1349 (1985)CrossRef
Metadata
Title
Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s
Authors
Dania Hirsch
Ilan Shimon
Yossi Manisterski
Nirit Aviran-Barak
Oren Amitai
Varda Nadler
Sandra Alboim
Vered Kopel
Gloria Tsvetov
Publication date
01-12-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1709-y

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.